(Total Views: 208)
Posted On: 09/30/2019 6:56:22 PM
Post# of 36564
BTW, with the deal between Olaregen and GNBT were these terms changed at all for Gene Biotherapeutics/Taxus:
Olaregen will pay $650,000 in cash up front and owe another $3.35 million in additional consideration that can consist of royalties on worldwide net sales, accelerated royalties in the form of lump sum cash payments based on capital investments received by Olaregen or the sale of the Excellagen technology platform to a third party.
Olaregen will pay $650,000 in cash up front and owe another $3.35 million in additional consideration that can consist of royalties on worldwide net sales, accelerated royalties in the form of lump sum cash payments based on capital investments received by Olaregen or the sale of the Excellagen technology platform to a third party.
(0)
(0)
